De-risk drug development and clinical trials with a product that’s transforming outdated approaches to drug discovery in oncology.
My Intelligent Machines makes it possible to reduce the costs, time, and failure rates associated with your clinical trials. With our SaaS product for target and indication prioritization and biomarker discovery in oncology, you and your team can:
- Access scientific insights to support strategic decisions on target and indication prioritization at pre-clinical stage to derisk drug development and increase return on investment
- Increase success rate of clinical trials for new targeted and immune therapies
- Explore new potent combined therapies
- Accelerate early high-value biomarkers to accelerate companion test development
Key product features and benefits
- Uses expression data from 16,000 patients across more than 200 cancer types
- Provides key insights on drug MOAs in individual patient contexts
- Identifies 30 to 200 genetic interactors of the drug target (focus genes) in minutes
- Requires the name of the drug target only
- Outperforms prediction of good responders based on target expression level only
- Performs equally well for new drug targets and those associated with FDA-approved drugs because MIMs’ method is not trained on clinical data
- Identifies combined therapy opportunities
- Available in subscription and pay-as-you-go models
To celebrate the launch of our augmented-intelligence product for target and indication prioritization and biomarker discovery in oncology, we are offering free 30-day trials and special promotional pricing.